Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Debt (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Non-Current Debt for 4 consecutive years, with $50.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 14.03% to $50.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.1 million through Dec 2025, up 14.03% year-over-year, with the annual reading at $50.1 million for FY2025, 14.03% up from the prior year.
  • Non-Current Debt hit $50.1 million in Q4 2025 for Taysha Gene Therapies, down from $50.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $50.9 million in Q3 2025 to a low of $37.4 million in Q1 2022.
  • Historically, Non-Current Debt has averaged $41.0 million across 4 years, with a median of $39.5 million in 2023.
  • Biggest five-year swings in Non-Current Debt: fell 1.35% in 2024 and later increased 18.34% in 2025.
  • Year by year, Non-Current Debt stood at $38.0 million in 2022, then grew by 6.69% to $40.5 million in 2023, then grew by 8.48% to $43.9 million in 2024, then rose by 14.03% to $50.1 million in 2025.
  • Business Quant data shows Non-Current Debt for TSHA at $50.1 million in Q4 2025, $50.9 million in Q3 2025, and $41.1 million in Q2 2025.